We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
+4.76%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$298M
AUM Growth
-$31.1M
Cap. Flow
-$7.8M
Cap. Flow %
-2.62%
Top 10 Hldgs %
83.41%
Holding
29
New
–
Increased
9
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$9.06M
2
OREX
Orexigen Therapeutics, Inc.
OREX
+$4.77M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$2.54M
4
EPZM
Epizyme, Inc
EPZM
+$2.22M
5
NVET
Nexvet Biopharma plc Ordinary Shares
NVET
+$654K

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$12.2M
2
AERI
Aerie Pharmaceuticals
AERI
+$3.92M
3
XLRN
Acceleron Pharma
XLRN
+$2.2M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$1.37M
5
BITI
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
+$1.06M

Sector Composition

Rank Sector Weight
1 Healthcare 65.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
$75.4M 25.29%
4,087,900
– –
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$46.6M 15.63%
331,399
-89,948
-21% -$12.2M
ADAP
3
DELISTED
Adaptimmune Therapeutics
ADAP
$21.2M 7.12%
1,761,567
+4,299
+0.2% +$42.1K
UAM
4
DELISTED
Universal American Corp
UAM
$19.7M 6.61%
2,814,883
– –
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$18.6M 6.23%
1,159,795
+150,000
+15% +$2.22M
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
$18M 6.03%
738,361
-167,956
-19% -$3.92M
RGLS
7
DELISTED
Regulus Therapeutics
RGLS
$15.3M 5.12%
14,589
+3
+0% +$3.01K
ALDR
8
DELISTED
Alder Biopharmaceuticals
ALDR
$13.9M 4.65%
419,997
+75,227
+22% +$2.54M
OREX
9
DELISTED
Orexigen Therapeutics, Inc.
OREX
$10.7M 3.59%
622,505
+200,000
+47% +$4.77M
LRMR icon
10
Larimar Therapeutics
LRMR
$416M
$9.36M 3.14%
124,034
+56,426
+83% +$9.06M
ARDX icon
11
Ardelyx
ARDX
$1.24B
$8.67M 2.91%
478,297
-38,993
-8% -$726K
NSTG
12
DELISTED
NanoString Technologies, Inc.
NSTG
$7.2M 2.41%
489,486
+25,000
+5% +$368K
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$6.7M 2.25%
137,458
-61,259
-31% -$2.2M
BDSI
14
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$4.54M 1.52%
947,815
+66,253
+8% +$376K
ANAC
15
CALL
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$3.5M 1.17%
31,000
– –
ANAC
16
PUT
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$3.5M 1.17%
31,000
– –
QTNT
17
DELISTED
Quotient Limited Ordinary Shares
QTNT
$3.08M 1.03%
4,804
-2,477
-34% -$1.37M
NVET
18
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$2.98M 1%
874,001
+165,669
+23% +$654K
RGNX icon
19
Regenxbio
RGNX
$623M
$2.6M 0.87%
156,741
– –
SCYX icon
20
SCYNEXIS
SCYX
$37M
$2.09M 0.7%
4,215
– –
BDSI
21
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.49M 0.5%
310,000
– –
SIOX
22
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.17M 0.39%
8,125
– –
BDSI
23
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.01M 0.34%
210,000
-100,000
-32% -$567K
NDRM
24
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$951K 0.32%
55,779
-21,022
-27% -$409K
RGLS
25
CALL
DELISTED
Regulus Therapeutics
RGLS
– –
-2,083
Closed -$1.64M
1
2

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q4 2015 Portfolio in Review

As of Q4 2015, Foresite Capital Management II held 29 positions worth $298M, down 9.4% from $329M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Foresite Capital Management II's Q4 2015 filing shows 9 increased, 7 reduced and 5 closed positions. The largest sale was Chinook Therapeutics, Inc. Common Stock, an estimated $12.2M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 58% a quarter earlier.

  • Foresite Capital Management II added most to Larimar Therapeutics in Q4 2015, an estimated $9.06M increase.
  • Foresite Capital Management II's biggest Q4 2015 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $12.2M.
  • Foresite Capital Management II fully exited BIOTIE THERAPIES CORP SPONSORED ADR in Q4 2015, selling an estimated $1.06M.
  • Foresite Capital Management II's ten largest holdings make up 83% of its $298M portfolio in Q4 2015.
  • Foresite Capital Management II opened 0 new positions and closed 5 in Q4 2015.
  • Foresite Capital Management II's portfolio value fell 9.4% quarter-over-quarter to $298M.

Based on Foresite Capital Management II's 13F filing for Q4 2015, filed 12 Feb 2016.